Compare LQDA & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | NATL |
|---|---|---|
| Founded | 2004 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2018 | N/A |
| Metric | LQDA | NATL |
|---|---|---|
| Price | $37.68 | $39.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $38.60 | ★ $42.75 |
| AVG Volume (30 Days) | ★ 1.9M | 353.9K |
| Earning Date | 11-03-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.74 |
| Revenue | $69,216,000.00 | ★ $4,322,000,000.00 |
| Revenue This Year | $1,005.03 | $2.83 |
| Revenue Next Year | $204.13 | $3.96 |
| P/E Ratio | ★ N/A | $22.94 |
| Revenue Growth | ★ 343.41 | 0.63 |
| 52 Week Low | $11.26 | $22.30 |
| 52 Week High | $41.57 | $42.23 |
| Indicator | LQDA | NATL |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 58.04 |
| Support Level | $29.41 | $39.08 |
| Resistance Level | $41.57 | $41.01 |
| Average True Range (ATR) | 3.03 | 1.09 |
| MACD | 0.43 | 0.10 |
| Stochastic Oscillator | 68.38 | 75.87 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.